Skip to main content

Breast Cancer

Edited by: Dr Marc Lippman

The Breast Cancer Collection is an invitation-only sister title of the Springer subscription journal, Breast Cancer Research and Treatment (BREA).

Invited submissions should choose the Breast Cancer Collection during submission, and include the invitation letter from Dr Lippman in their SpringerPlus cover letter.

For more information about how you can be considered for the Breast Cancer Collection, please speak to the editorial team at BREA.


Collection Articles:

Page 3 of 4

  1. Taxanes are a cornerstone treatment in early and advanced stage breast cancer and in other common solid tumor malignancies; however, the development of chemotherapy induced peripheral neuropathy (CIPN) often n...

    Authors: Bhavana Bhatnagar, Steven Gilmore, Olga Goloubeva, Colleen Pelser, Michelle Medeiros, Saranya Chumsri, Katherine Tkaczuk, Martin Edelman and Ting Bao
    Citation: SpringerPlus 2014 3:366
  2. Docetaxel, a chemotherapeutic agent, induces high rates of transient chemotherapy-induced amenorrhea (CIA) when used as adjuvant chemotherapy for premenopausal women with breast cancer. Clinical laboratory dat...

    Authors: Keiko Yoshimura and Yoshihiko Furuya
    Citation: SpringerPlus 2014 3:352
  3. Metastatic breast cancer (MBC) patients are treated with a variety of regimens with differing side effects that can reduce the patients’ quality of life. This study assessed the willingness to pay (WTP) to avo...

    Authors: Deepa Lalla, Rashad Carlton, Eduardo Santos, Thomas Bramley and Anna D’Souza
    Citation: SpringerPlus 2014 3:350
  4. Associations between population-based screening, breast carcinoma detection modes and breast carcinoma death have not been studied using nationwide data at individual level. We evaluated these in Finland, wher...

    Authors: Tytti Sarkeala, Tapio Luostarinen, Tadeusz Dyba and Ahti Anttila
    Citation: SpringerPlus 2014 3:348
  5. External beam radiotherapy (EBRT) is the gold standard adjuvant treatment after breast conserving surgery although a recent phase 3 trial has shown the non-inferiority of intraoperative radiotherapy (IORT).

    Authors: David K Woolf, Norman R Williams, Raheleh Bakshi, Seyed Yazdan Madani, David J Eaton, Sara Fawcitt, Katharine Pigott, Susan Short and Mohammed Keshtgar
    Citation: SpringerPlus 2014 3:329
  6. Patients with breast cancer and bone metastases often experience skeletal complications (skeletal-related events [SREs]: pathologic fracture, radiation to bone, surgery to bone or spinal cord compression). Pro...

    Authors: Diana Lüftner, Vito Lorusso, Ignacio Duran, Guy Hechmati, Cristina Garzon-Rodriguez, John Ashcroft, Amit Bahl, Prayashi Ghelani, Rachel Wei, Emma Thomas and Herbert Hoefeler
    Citation: SpringerPlus 2014 3:328
  7. The present study aimed to measure the thickness of the subcutaneous adipose tissue (SAT) at the site of the surgical incision for axillary lymph node dissection (ALND) and to record potential anatomical varia...

    Authors: Emerson Wander Silva Soares
    Citation: SpringerPlus 2014 3:306
  8. Gemcitabine/taxanes-based combination shows anti-tumor activity for the treatment of metastatic breast cancer, but there is a debate regarding the advantages of gemcitabine and taxanes regimens as a first-line...

    Authors: Qian Hu, Jun-xia Jiang, Long Luo, Xing Yang, Xiao Lin, Xiao-xiao Dinglin, Wei Zhang, Jun-yan Wu and He-rui Yao
    Citation: SpringerPlus 2014 3:293
  9. To overcome cytochrome P450 2D6 (CYP2D6) mediated tamoxifen resistance in postmenopausal early breast cancer, CYP2D6 phenotype-adjusted tamoxifen dosing in patients with impaired CYP2D6 metabolism and/or the a...

    Authors: Kristin Dickschen, Thomas Eissing, Thomas Mürdter, Matthias Schwab, Stefan Willmann and Georg Hempel
    Citation: SpringerPlus 2014 3:285
  10. Despite evidence supporting at least five years of endocrine therapy for early breast cancer, many women discontinue therapy early. We investigated the impact of initial therapy type and specific comorbidities...

    Authors: Anna Kemp, David B Preen, Christobel Saunders, Frances Boyle, Max Bulsara, Eva Malacova and Elizabeth E Roughead
    Citation: SpringerPlus 2014 3:282
  11. Selective Estrogen Receptor Modulators (SERMs) reduce the risk of breast cancer for women at increased risk by 38%. However, uptake is extremely low and the reasons for this are not completely understood. The ...

    Authors: Angelique F Ralph, Brittany Ager, Melanie L Bell, Ian M Collins, Lesley Andrews, Kathy Tucker, Nicole O’Reilly, Kelly-Anne Phillips and Phyllis Butow
    Citation: SpringerPlus 2014 3:264
  12. To investigate the association between pre- and postoperative alcohol consumption and risk for early breast cancer events, since the association between alcohol consumption and prognosis in breast cancer patie...

    Authors: Maria Simonsson, Andrea Markkula, Pär-Ola Bendahl, Carsten Rose, Christian Ingvar and Helena Jernström
    Citation: SpringerPlus 2014 3:261
  13. We sought to compare the economic impact of treatment-related adverse events (AEs) in patients with metastatic breast cancer (mBC) using taxane- or capecitabine-based treatment regimens as either first- or sec...

    Authors: Ryan N Hansen, Scott D Ramsey, Deepa Lalla, Anthony Masaquel, Tripthi Kamath, Melissa Brammer, Sara A Hurvitz and Sean D Sullivan
    Citation: SpringerPlus 2014 3:259
  14. Adding antiangiogenic therapy to standard chemotherapy has improved response rates and progression-free survival in metastatic breast cancer (BC) patients. This phase II study evaluated cardiac safety of bevac...

    Authors: Sara A Hurvitz, Linda D Bosserman, David Chan, Christopher T Hagenstad, Frederick C Kass, Frederick P Smith, Gladys I Rodriguez, Barrett H Childs and Dennis J Slamon
    Citation: SpringerPlus 2014 3:244
  15. Few studies have compared treatment patterns, healthcare resource utilization (HRU), and costs in patients with metastatic breast cancer (mBC) receiving HER2 directed therapy. This study evaluated these outcom...

    Authors: Annie Guérin, Deepa Lalla, Geneviève Gauthier, Amy Styles, Eric Q Wu, Anthony Masaquel and Melissa G Brammer
    Citation: SpringerPlus 2014 3:236
  16. The probability of detecting radiologically evident metastatic disease in asymptomatic women with newly diagnosed operable breast cancer is low. Despite the recommendations of most practice guidelines imaging ...

    Authors: Demetrios Simos, Brian Hutton, Ian D Graham, Angel Arnaout, Jean-Michel Caudrelier, Sasha Mazzarello and Mark Clemons
    Citation: SpringerPlus 2014 3:176
  17. The most effective dietary pattern for breast cancer prevention has been greatly debated in recent years. Studies have examined hypocaloric diets, with particular emphasis on macronutrient composition, yieldin...

    Authors: Adana AM Llanos, Jessica L Krok, Juan Peng, Michael L Pennell, Susan Olivo-Marston, Mara Z Vitolins, Cecilia R DeGraffinreid and Electra D Paskett
    Citation: SpringerPlus 2014 3:175
  18. The main objective of this prospective study was to obtain a better understanding of the body composition and vital sign measures of cancers survivors (CS) when compared to regular (R) patients.

    Authors: David H Jones, Melisa Nestore, Sara Henophy, Julia Cousin and Alain Steve Comtois
    Citation: SpringerPlus 2014 3:150
  19. Although prognostic differences between screen-detected, interval and symptomatic breast cancers are known, factors associated with wait times to diagnosis among these three groups have not been studied.

    Authors: Amalia Plotogea, Anna M Chiarelli, Lucia Mirea, Maegan V Prummel, Nelson Chong, Rene S Shumak, Frances P O’Malley and Claire MB Holloway
    Citation: SpringerPlus 2014 3:125
  20. Lapatinib in combination with capecitabine is approved for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal growth factor receptor 2 (HER2) and w...

    Authors: Helen Kent Chew, Lee Schwartzberg, Suprith Badarinath, Peter Rubin, Grace Shumaker, James Daugherty, Michelle DeSilvio and Janine Mahoney
    Citation: SpringerPlus 2014 3:108
  21. This retrospective study evaluated the impact of intermediate Recurrence Score® results on adjuvant treatment decisions in estrogen receptor-positive (ER+) early invasive breast cancer, comparing treatment recomm...

    Authors: Georgeta Fried and Mor Moskovitz
    Citation: SpringerPlus 2014 3:71
  22. The aim of the present study was to investigate the long-term impact of prognostic factors in invasive lobular carcinoma (ILC) of the breast, with a primary focus on Ki67 and histological grade, alone and in c...

    Authors: Ulrik Narbe, Pär-Ola Bendahl, Dorthe Grabau, Lisa Rydén, Christian Ingvar and Mårten Fernö
    Citation: SpringerPlus 2014 3:70
  23. Expression of transcription-factors as Slug and Sox9 was recently described to determine mammary stem-cell state. Sox10 was previously shown to be present also in breast cancer. Protein overexpression of Slug,...

    Authors: Cosima Riemenschnitter, Ivett Teleki, Verena Tischler, Wenjun Guo and Zsuzsanna Varga
    Citation: SpringerPlus 2013 2:695
  24. Decreased lean body mass (LBM) is common in breast cancer survivors yet currently there is a lack of information regarding the determinants of LBM after treatment, in particular, the effect of physical activit...

    Authors: Cameron McDonald, Judy Bauer, Sandra Capra and Mary Waterhouse
    Citation: SpringerPlus 2013 2:681
  25. Chronic internal inflammation secondary to adiposity is a risk factor for sporadic breast cancer and Post-Menopausal Breast Cancer (PMBC) is largely defined as such. Adiposity is one of the clinical criteria f...

    Authors: Xiaowei Sherry Yan, Jill Barnholtz-Sloan, Xin Chu, Ling Li, Ryan Colonie, Jessica Webster, Diane Smelser, Nikitaban Patel, Jeffery Prichard and Azadeh Stark
    Citation: SpringerPlus 2013 2:638
  26. The aim of this study was to describe the imaging features of patients with invasive ductolobular carcinoma of the breast in comparison with the proportion of the lobular component.

    Authors: Gisela LG Menezes, Maurice AAJ van den Bosch, Emily L Postma, Mary–Ann El Sharouni, Helena M Verkooijen, Paul J van Diest and Ruud M Pijnappel
    Citation: SpringerPlus 2013 2:621
  27. Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen....

    Authors: Vineetha K Edavana, Rosalind B Penney, Aiwei Yao-Borengasser, Suzanne Williams, Lora Rogers, Ishwori B Dhakal and Susan Kadlubar
    Citation: SpringerPlus 2013 2:620
  28. Locoregional therapy is rarely the standard of care for De Novo stage IV breast cancer but usually used for palliation of symptoms. This retrospective study aimed to determine whether surgery or radiation woul...

    Authors: Peng-Yu Chen, Skye Hung-Chun Cheng, Chen-Fang Hung, Ben-Long Yu and Chii-Ming Chen
    Citation: SpringerPlus 2013 2:589
  29. The purpose of this study is to present our first results of sentinel node analysis (SLN) by one step nucleic acid amplification (OSNA) in routine clinical practice in our centre and compare them with the resu...

    Authors: Ana Santaballa, Helena De La Cueva, Carmen Salvador, Ana M García-Martínez, María J Guarín, David Lorente, Laura Palomar, Ismael Aznar, Fernando Dobón and Pilar Bello
    Citation: SpringerPlus 2013 2:542
  30. Breast cancer is characterized by late presentation and significant morbidity and mortality in developing countries. Breast screening aids in early detection of breast cancer. Nurses are uniquely placed to pro...

    Authors: Miriam Mutebi, Ronald Wasike, Ahmed Mushtaq, Aideed Kahie and Stephen Ntoburi
    Citation: SpringerPlus 2013 2:528
  31. The purpose of this study was to determine if race is a factor on overall survival when stage at diagnosis is compared. In this study, a total of 93 women with triple negative breast cancer (TNBC) were evaluat...

    Authors: Athena Starlard-Davenport, Katherine Glover-Collins, Issam Mahkoul, Laura Hutchins, Kent Westbrook, Soheila Korourian, Kimberly Enoch, Michael Preston, Shakia N Jackson, V Suzanne Klimberg and Ronda Henry-Tillman
    Citation: SpringerPlus 2013 2:516
  32. Mucinous breast carcinoma (MBC) is classified into mixed mucinous breast carcinoma (MMBC) and pure mucinous breast carcinoma (PMBC) based on whether the tumor is with or without a component of invasive ductal ...

    Authors: Shinichiro Kashiwagi, Naoyoshi Onoda, Yuka Asano, Satoru Noda, Hidemi Kawajiri, Tsutomu Takashima, Masahiko Ohsawa, Seiichi Kitagawa and Kosei Hirakawa
    Citation: SpringerPlus 2013 2:481
  33. The significance of nodal metastasis in breast cancer is under discussion. We investigated the impact of variables of tumor chronology and tumor biology on the presence of lymph node metastases.

    Authors: Ann Smeets, Andries Ryckx, Ann Belmans, Hans Wildiers, Patrick Neven, Giuseppe Floris, Patrick Schöffski and Marie-Rose Christiaens
    Citation: SpringerPlus 2013 2:480
  34. For the first time the incidence and mortality of breast cancer were estimated in French Guiana, an overseas French Territory of South America. A certified cancer registry collected exhaustive data on breast c...

    Authors: Tristan Roue, Angela Fior, Juliette Plenet, Sophie Belliardo and Mathieu Nacher
    Citation: SpringerPlus 2013 2:471
  35. Here we assessed associations between null mutations in glutathione-S-transferase (GST)T1 and GSTM1 genes, and the rs1695 polymorphism in GSTP1 (Ile105Val), and risk of breast cancer-specific (n=45) and all-cause...

    Authors: Catherine Duggan, Rachel Ballard-Barbash, Richard N Baumgartner, Kathy B Baumgartner, Leslie Bernstein and Anne McTiernan
    Citation: SpringerPlus 2013 2:450
  36. Although preliminary reports suggest that ALK gene amplification may occur in inflammatory breast cancer (IBC), data are limited. We performed a comprehensive investigation of the status of ALK gene in IBC.

    Authors: Savitri Krishnamurthy, Wendy Woodward, Wei Yang, James M Reuben, James Tepperberg, Dai Ogura, Shin-ichiro Niwa, Lei Huo, Yun Gong, Randa El-Zein, Ana M Gonzalez-Angulo, Mariana Chavez-MacGregor, Ricardo Alvarez, Anthony Lucci, Vicente Valero and Naoto T Ueno
    Citation: SpringerPlus 2013 2:409
  37. Researchers have recently shown an increased interest in free radicals and their role in the tumor microenvironment. Free radicals are molecules with high instability and reactivity due to the presence of an o...

    Authors: Sandra Ríos-Arrabal, Francisco Artacho-Cordón, Josefa León, Elisa Román-Marinetto, María del Mar Salinas-Asensio, Irene Calvente and Maria Isabel Núñez
    Citation: SpringerPlus 2013 2:404
  38. We evaluate trade-offs between quality of life (QoL) and survival improvement for two chemotherapy regimens in advanced breast cancer. We also report on the long-term survival of patients in the ANZ 8614 clini...

    Authors: Chee Khoon Lee, Val J Gebski, Alan S Coates, Anne-Sophie Veillard, Vernon Harvey, Martin HN Tattersall, Michael J Byrne, Brian Brigham, John Forbes and R John Simes
    Citation: SpringerPlus 2013 2:391
  39. Longer times from diagnosis to breast cancer treatment are associated with poorer prognosis. This study examined factors associated with wait times by phase in the breast cancer treatment pathway.

    Authors: Amalia Plotogea, Anna M Chiarelli, Lucia Mirea, Maegan V Prummel, Nelson Chong, Rene S Shumak, Frances P O’Malley and Claire M B Holloway
    Citation: SpringerPlus 2013 2:388
  40. Testing for human epidermal growth factor receptor-2 (HER-2) in breast cancer is performed by either immunohistochemistry (IHC) or in situ hybridization (ISH). The growth factor receptor-bound protein-7 (GRB7)...

    Authors: Shiuh-Wen Luoh, Betsy Ramsey, Amy Hanlon Newell, Megan Troxell, Zhi Hu, Koei Chin, Paul Spellman, Susan Olson and Edward Keenan
    Citation: SpringerPlus 2013 2:386
  41. Recently, therapies targeting the biological characteristics of individual cancers according to markers indicating underlying molecular biological mechanisms have become available. Core needle biopsy (CNB) is ...

    Authors: Shinichiro Kashiwagi, Naoyoshi Onoda, Yuka Asano, Satoru Noda, Hidemi Kawajiri, Tsutomu Takashima, Masahiko Ohsawa, Seiichi Kitagawa and Kosei Hirakawa
    Citation: SpringerPlus 2013 2:372
  42. In the last decade, more and more oncology centers are challenged with complementary medicine (CM) integration within supportive breast cancer care. Quality of life (QOL) improvement and attenuation of oncolog...

    Authors: Eran Ben-Arye, Elad Schiff, Moti Levy, Orit Gressel Raz, Yael Barak and Gil Bar-Sela
    Citation: SpringerPlus 2013 2:364
  43. Studies have demonstrated lower rates of breast cancer survival for Black versus White women. Factors implicated include later stages at diagnosis, differences in tumor biology, and lower compliance rates to a...

    Authors: Sumita S Bhatta, Ningqi Hou, Zakiya N Moton, Blase N Polite, Gini F Fleming, Olufunmilayo I Olopade, Dezheng Huo and Susan Hong
    Citation: SpringerPlus 2013 2:356
  44. Since the performance of surgical procedures of the axilla in the treatment of early breast cancer is decreasing, the role of axillary ultrasound (AUS) as staging procedere has newly to be addressed. The aim o...

    Authors: Angrit Stachs, Katja Göde, Steffi Hartmann, Bernd Stengel, Ulrike Nierling, Max Dieterich, Toralf Reimer and Bernd Gerber
    Citation: SpringerPlus 2013 2:350